

ATYPICAL PARKINSONIAN DISORDERS (PSP, CBD AND MSA)

Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) are life-limiting, adult-onset neurodegenerative diseases. PSP, CBD and MSA are often known as an “atypical Parkinsonisms” because of overlapping symptoms with Parkinson’s.



PREVALENCE

PSP: 6-10 people per 100,000

CBD: 2-4 people per 100,000

MSA: 2-5 people per 100,000

Note: These are likely underestimates because many people are misdiagnosed with another condition.



PROFOUND IMPACTS

The average life expectancy of PSP, CBD and MSA ranges from 5 to 10 years, nearly half that of people with Parkinson’s. Seeking a diagnosis consumes a third of this time. The emotional, physical and financial tolls of the disease on families are immense and require heavy utilization of healthcare resources.

SYMPTOMS AND DIAGNOSIS

A clinical diagnosis is made through a neurological exam, medical history, brain imaging and ruling out other conditions. Confirmation of these diagnoses can only be made through a post-mortem study of brain tissue.



SLOWNESS
AND
STIFFNESS



CHANGES IN
PERSONALITY
AND COGNITIVE
FUNCTIONING



ISSUES WITH
WALKING,
BALANCE,
POSTURE AND
COORDINATION



DIFFICULTY
SWALLOWING,
LEADING TO RISK OF
CHOKING AND LUNG
INFECTIONS



SLURRED
SPEECH AND
DIFFICULTY
EXPRESSING
WORDS



WEAKNESS OF EYE
MOVEMENTS AND
POOR VISION,
PARTICULARLY IN PSP

The list of symptoms above is not exhaustive and the presentation/progression of PSP, CBD and MSA is very individual.

RESEARCH: KNOWLEDGE GAPS AND OPPORTUNITIES

The cause of these diseases is unknown and there are no FDA- approved treatments at this time. There is an urgent need and opportunity to work together to:

Raise awareness to cut down time to diagnosis and getting the right care

Find reliable diagnostic markers (e.g., wearable devices, blood test, brain imaging)

Determine environmental and genetic risk factors for PSP, CBD and MSA

Develop effective treatments and, ultimately, a cure!



TREATMENT AND CARE

Currently, there is no known cure and there are no treatments to prevent PSP, CBD and MSA or slow the progression. Levodopa therapy, developed for Parkinson’s, is often used but may offer limited benefit. Medications, exercise and therapies are focused on safety and management of symptoms.



curePSP®
UNLOCKING THE SECRETS OF BRAIN DISEASE®

CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure of progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy. Science, community and hope are at the heart of CurePSP’s mission and all of our services. For more information, please visit www.curepsp.org or contact Jessica Shurer, MSW, LCSW, Director of Clinical Affairs and Advocacy, at shurer@curepsp.org